<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Current Report<BR>
Pursuant To Section&nbsp;13 or 15 (d)&nbsp;of the<BR>
Securities Exchange Act of 1934</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported) &#151;February&nbsp;7, 2006</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>NUCRYST PHARMACEUTICALS CORP.</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>(Exact name of registrant as specified in its charter)</B></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Alberta, Canada</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-51686</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>Not Applicable</B></TD>
</TR>
<TR valign="bottom">

<TD align="center" valign="top"><FONT style="font-size:8pt"><B>(State
or other jurisdiction of</B></FONT>
</TD>
    <TD>&nbsp;</TD>

<TD align="center" valign="top"><FONT style="font-size:8pt"><B>(Commission</B></FONT>
</TD>
    <TD>&nbsp;</TD>

<TD align="center" valign="top"><FONT style="font-size:8pt"><B>(I.R.S.
Employer</B></FONT></TD>
</TR>
<TR valign="bottom">

<TD align="center" valign="top"><FONT style="font-size:8pt"><B>incorporation
or organization)</B></FONT>
</TD>
    <TD>&nbsp;</TD>

<TD align="center" valign="top"><FONT style="font-size:8pt"><B>File
Number)</B></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="font-size:8pt"><B>Identification No.)</B></FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>NUCRYST Pharmaceuticals Corp.<BR>
50 Audubon Road<BR>
Wakefield, MA 01880</B><BR>
<FONT style="font-size:8pt"><B>(Address of principal executive offices)</B></FONT>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-size:8pt"><B>Registrant&#146;s
telephone number, including area code:</B></FONT> <B>(780)&nbsp;992-5326</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Not applicable</B><BR>
<FONT style="font-size:8pt"><B>(Former name or former address, if changed since last report)</B></FONT>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV style="border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (<I>see </I>General
Instruction A.2. below):
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">(Former name or former address, if changed since last report)
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">








<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Item&nbsp;8.01</I></B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Other Events.</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 3%">Please see Exhibit &#147;A&#148; attached.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Item&nbsp;9.01</I></B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Financial Statements and Exhibits.</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 3%">Exhibit &#147;A&#148; &#151; Press Release announcing Webcast of Conference Call to Discuss 2005 Fourth
Quarter and Year-End Results.
</DIV>


<P align="center" style="font-size: 10pt">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Nucryst Pharmaceuticals Corp.</B></FONT> <BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left"><B>/s/ Carol L. Amelio</B>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left"><B>Carol L. Amelio</B>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">DATE: February 14, 2006&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left"><B>General Counsel and Corporate Secretary</B>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="o30228o3022800.gif" alt="(NUCRYST LOGO)">
</DIV>


<DIV align="center" style="font-size: 14pt; margin-top: 18pt"><U><B>WEBCAST ADVISORY</B></U>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 6pt"><B>NUCRYST Pharmaceuticals<BR>
Webcast of Conference Call to Discuss<BR>
2005 Fourth Quarter and Year-End Results</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 6pt"><B>Wednesday February&nbsp;15, 2006<BR>
4:30 p.m. EST</B><BR>
<U><B>www.nucryst.com</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NUCRYST Pharmaceuticals Corp. will hold a webcast at 4:30 p.m. EST on Wednesday February&nbsp;15,
2006 regarding the company&#146;s 2005 fourth quarter and year-end results.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In addition to standard disclosure over wire services, a news release and financial statements will
be posted on the NUCRYST web site. To listen to the call live on the Internet, please go to
<U>www.nucryst.com</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Scott H. Gillis, President &#038; CEO and Eliot M. Lurier, Vice President, Finance and Administration
will participate on the call.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">An audio file of the call will be archived and posted on the NUCRYST web site.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NUCRYST Pharmaceuticals (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical
products that fight infection and inflammation based on its nanocrystalline silver technology.
Advanced wound care products with the company&#146;s SILCRYST&#153; coatings are sold by Smith &#038; Nephew plc
under an exclusive license in over 30 countries under its Acticoat&#153; trademark. NUCRYST is also
developing pharmaceutical products to address medical conditions that are characterized by both
infection and inflammation. The company has developed its nanocrystalline silver in a powder form
for use as an active pharmaceutical ingredient, referred to as NPI 32101.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">-30-
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For more information, please contact:<BR>
Gillian McArdle<BR>
(416)&nbsp;504-8464<BR>
info@nucryst.com

</DIV>


<P align="center" style="font-size: 10pt">
</DIV>


</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "o30228e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 11485}]
{"company-data": {"conformed-name": "NUCRYST Pharmaceuticals Corp.", "cik": "0001344674", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "A0", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-51686", "film-number": "06617948"}, "business-address": {"street1": "50 AUDUBON ROAD", "street2": "SUITE B", "city": "WAKEFIELD", "state": "MA", "zip": "01880", "phone": "781-224-1444"}, "mail-address": {"street1": "50 AUDUBON ROAD", "street2": "SUITE B", "city": "WAKEFIELD", "state": "MA", "zip": "01880"}}
e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant To Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) —February 7, 2006
NUCRYST PHARMACEUTICALS CORP.
(Exact name of registrant as specified in its charter)
Alberta, Canada
000-51686
Not Applicable
(State
or other jurisdiction of
(Commission
(I.R.S.
Employer
incorporation
or organization)
File
Number)
Identification No.)
NUCRYST Pharmaceuticals Corp.
50 Audubon Road
Wakefield, MA 01880
(Address of principal executive offices)
Registrant's
telephone number, including area code:
(780) 992-5326
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (
see
General
Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
(Former name or former address, if changed since last report)
Item 8.01
Other Events.
Please see Exhibit "A" attached.
Item 9.01
Financial Statements and Exhibits.
Exhibit "A" — Press Release announcing Webcast of Conference Call to Discuss 2005 Fourth
Quarter and Year-End Results.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Nucryst Pharmaceuticals Corp.
By:
/s/ Carol L. Amelio
Carol L. Amelio
DATE: February 14, 2006
General Counsel and Corporate Secretary
WEBCAST ADVISORY
NUCRYST Pharmaceuticals
Webcast of Conference Call to Discuss
2005 Fourth Quarter and Year-End Results
Wednesday February 15, 2006
4:30 p.m. EST
www.nucryst.com
NUCRYST Pharmaceuticals Corp. will hold a webcast at 4:30 p.m. EST on Wednesday February 15,
2006 regarding the company's 2005 fourth quarter and year-end results.
In addition to standard disclosure over wire services, a news release and financial statements will
be posted on the NUCRYST web site. To listen to the call live on the Internet, please go to
www.nucryst.com
.
Scott H. Gillis, President & CEO and Eliot M. Lurier, Vice President, Finance and Administration
will participate on the call.
An audio file of the call will be archived and posted on the NUCRYST web site.
NUCRYST Pharmaceuticals (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical
products that fight infection and inflammation based on its nanocrystalline silver technology.
Advanced wound care products with the company's SILCRYST™ coatings are sold by Smith & Nephew plc
under an exclusive license in over 30 countries under its Acticoat™ trademark. NUCRYST is also
developing pharmaceutical products to address medical conditions that are characterized by both
infection and inflammation. The company has developed its nanocrystalline silver in a powder form
for use as an active pharmaceutical ingredient, referred to as NPI 32101.
-30-
For more information, please contact:
Gillian McArdle
(416) 504-8464
info@nucryst.com